2-氨基-7-[二(2-氯乙基)氨基]-3,4-二氢-1H-萘-2-羧酸 | 106094-83-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 2-氨基-7-[二(2-氯乙基)氨基]-3,4-二氢-1H-萘-2-羧酸
• 中文别名: 9H-咪唑并[1,2-a]嘌呤-9-酮,3,5-二乙酰基-3,5,6,7-四氢-6,7-二羟基-
• 英文名称: (+/-)-7-[bis(2-chloroethyl)amino]-2-amino-1,2,3,4-tetrahydro-2-naphthoic acid
• 英文别名: DL-2-NAM-7；DL-2-amino-7-bis(2-chloroethyl)amino-1,2,3,4-tetrahydro-2-naphthoic acid；2-Amino-7-[bis-(2-chloro-ethyl)-amino]-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid；2-amino-7-[bis(2-chloroethyl)amino]-3,4-dihydro-1H-naphthalene-2-carboxylic acid
• CAS: 106094-83-1
• 化学式: C₁₅H₂₀Cl₂N₂O₂
• 分子量: 331.242
• InChiKey: YHWFDBWKAOPRRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  66.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  DL-7'-spiro-2,5-dione 在 盐酸 、 水 作用下， 生成 2-氨基-7-[二(2-氯乙基)氨基]-3,4-二氢-1H-萘-2-羧酸
  参考文献：
  名称：

  Regiospecific and conformationally restrained analogs of melphalan and dl-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood–brain barrier

  摘要：

  Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 have been synthesized and their affinities for the large neutral amino acid transporter (LAT1) of the blood-brain barrier have been determined to assess their potential for accessing the CNS via facilitated transport. Several analogs had K-i values in the range 2.1-8.5 mu M with greater affinities than that of either L-phenylalanine (K-i = 11 mu M) or melphalan (K-i = 55 mu M), but lower than DL-2-NAM-7 (K-i = 0.08 mu M). The results indicate that regiospecific positioning of the mustard moiety on the aromatic ring in these analogs is very important for optimal affinity for the large neutral amino acid transporter, and that conformational restriction of the DL-2-NAM-7 molecule in benzonorbornane and indane analogs leads to 25- to 60-fold loss, respectively, in affinity. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.04.086

文献信息

• VISTICA, DAVID T.
  作者：VISTICA, DAVID T.

  DOI：——

  日期：——
• US4772632A
  申请人：——

  公开号：US4772632A

  公开（公告）日：1988-09-20
• US5284774A
  申请人：——

  公开号：US5284774A

  公开（公告）日：1994-02-08
• [EN] MICELLAR NANOPARTICLES AND USES THEREOF<br/>[FR] NANOPARTICULES MICELLAIRES ET UTILISATIONS ASSOCIÉES
  申请人：BIORCHESTRA CO LTD

  公开号：WO2020261227A1

  公开（公告）日：2020-12-30

  The present disclosure includes cationic carrier units comprising (i) a water soluble polymer, (ii) a positively charged carrier, and (iii) an adjuvant moiety, wherein when the cationic carrier unit is mixed with an anionic payload (e.g., an antisense oligonucleotide) that electrostatically interacts with the cationic carrier unit, the resulting composition self-organizes into a micelle encapsulating the anionic payload in its core. The cationic carrier units can also comprise a tissue specific targeting moiety, which would be displayed on the surface of the micelle. The disclosure also includes micelles comprising the cationic carrier units of the disclosure, methods of manufacture of cationic carrier units and micelles, pharmaceutical compositions comprising the micelles, and also methods of treating diseases or conditions comprising administering the micelles to a subject in need thereof.
• [EN] MICELLAR NANOPARTICLES AND USES THEREOF<br/>[FR] NANOPARTICULES MICELLAIRES ET LEURS UTILISATIONS
  申请人：[en]BIORCHESTRA CO., LTD.

  公开号：WO2022144811A1

  公开（公告）日：2022-07-07

  The present disclosure includes cationic carrier units comprising (i) a water-soluble polymer, (ii) a positively charged carrier, (iii) a hydrophobic moiety, and (iv) a crosslinking moiety, wherein when the cationic carrier unit is mixed with an anionic payload (e.g., an antisense oligonucleotide) that electrostatically interacts with the cationic carrier unit, the resulting composition self-organizes into a micelle encapsulating the anionic payload in its core. The cationic carrier units can also comprise a tissue specific targeting moiety, which would be displayed on the surface of the micelle. The disclosure also includes micelles comprising the cationic carrier units of the disclosure, methods of manufacture of cationic carrier units and micelles, pharmaceutical compositions comprising the micelles, and also methods of treating diseases or conditions comprising administering the micelles to a subject in need thereof.